Penile cancer is a rare urologic malignancy. In Australia, the incidence is low with the reported incidence ranging from 0.45-1.7 per 100, 000 men¹.  Despite its rarity, penile cancer has a disappointingly high mortality and morbidity rate. In Australia, evidence based practice is limited as only a small number of published results are available to base treatment recommendations. We herein present the first large Australian series to review the mortality trends of penile cancer. The Victoria Cancer Council registry (VCR) was used to report the cancer-specific survival based on tumor classification and histological grade over the last 15 years. We have identified 251 patients who underwent surgery for penile cancer from January 1998 to December 2013. Primary treatment options for penile cancer include circumcision, local excision, partial penectomy and total penectomy. Almost half of the cohort had pT1 disease (51.4%) followed by pT2 disease (28.3%) and pT3/4 (11.2%) disease. A small number of patients had carcinoma in situ (7.2%). The surgical approach to penile cancer in this cohort include circumcision (n=34, 13.5%), local excision (n=54, 21.5%), partial penectomy (n=124, 49.4%) and total penectomy (n=39, 15.5%). Tumour (pT) stage was found to be statistically significant in associating with treatment types. The Kaplan-Meier curve for cancer-specific survival (CSS) according to pathological T classification. The 5-year CSS probability for pT1, pT2, and pT3/4 disease was 89%, 53% (CI 21%-85%), 23% (CI 6%-24%), respectively (P < 0.001). The CSS in this cohort was worse compared to current published literature. Factors that may contribute to this include under utilisation of regional lymph node sampling which has been shown to be a prognostic factor in penile cancer. More research is required to assist in forming local guidelines to better managed this rare urologic malignancy.